托拉塞米对心力衰竭患者血流动力学与神经激素应激及心脏重构的影响——TORNADO:一项随机对照试验的研究方案
TORNADO 是一项多中心、随机、开放、盲法终点的Ⅳ期试验,纳入120例NYHA心功能Ⅱ-Ⅳ级、已接受最佳心衰治疗且有袢利尿剂使用指征的慢性心衰患者,1:1随机接受呋塞米或托拉塞米(等效剂量4:1替换),随访至少6个月,比较两者对血流动力学与神经激素代偿、心肌重构的临床及生化指标的影响。
要点
- 多中心随机开放盲法终点Ⅳ期试验,120例NYHA Ⅱ-Ⅳ级心衰患者,1:1随机分组。
- 呋塞米继续固定剂量或按4:1等效剂量替换为托拉塞米,随访至少6个月。
- 主要目标比较托拉塞米与呋塞米对血流动力学与神经激素代偿及心肌重构的影响。
核心结论
- 尽管利尿剂应用已有数十年历史,关于利尿剂治疗的认识仍不令人满意。
- 报告非常令人鼓舞,提示托拉塞米具有有益效应,因此需要进一步研究托拉塞米与呋塞米相比的整体效应,这可能转化为心衰患者生活质量的改善和更好的预后。
研究设计与样本
- 多中心、随机、开放、盲法终点的Ⅳ期试验。
- 纳入120例NYHA功能Ⅱ-Ⅳ级、接受最佳心衰治疗且有袢利尿剂使用指征的心衰患者。
- 入组时患者病情稳定,使用固定剂量袢利尿剂;按1:1随机接受呋塞米或托拉塞米治疗。
- 随机后继续当前固定剂量呋塞米,或按4:1等效剂量替换为托拉塞米。
- 研究包括两次对照访视(入组后3个月和6个月),最短随访6个月。
主要发现
- 评估包括临床检查、生活质量问卷、实验室检查、超声心动图、心电图、24小时动态心电图监测、6分钟步行试验和液体潴留评估。
- 观察期间评估任何剂量调整的需求。
- 主要目标是比较托拉塞米与呋塞米对血流动力学与神经激素代偿及心肌重构的临床和生化指标的影响。
- 次要目标包括监测心衰体征和症状变化、NYHA功能分级、生活质量、剂量变化、再入院率和死亡率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately 50% of heart failure patients are readmitted to hospital within 6 months, owing to deterioration of their condition. Thus, symptomatic treatment of heart failure requires significant improvement. The aim of this study is to compare the effects of torasemide and furosemide on biochemical parameters of haemodynamic and neurohormonal compensation, myocardial remodelling, clinical outcomes and quality of life in patients with chronic heart failure. METHODS: This is a multicentre, randomized, open, blinded endpoint phase-IV trial. The study includes 120 heart failure patients in NYHA (New York Heart Association) functional class II-IV, treated with optimal heart failure therapy, with indications for use of loop diuretics. At enrolment, patients are stable, with a fixed dose of loop diuretics. Patients are randomized to treatment with furosemide or torasemide (randomization 1:1). After randomization, the current fixed dose of furosemide is continued or is replaced by an equipotential dose of torasemide (4:1). The study consists of two control visits (3 and 6 months after enrolment) with minimal follow-up of 6 months. Assessment involves clinical examination, Quality of Life Questionnaire, laboratory tests, echocardiography, electrocardiography, 24 h Holter-electrocardiography monitoring, 6 -min walk test and assessment of fluid retention. Any need for dose adjustment is assessed during the observation. The primary objective is to compare the effects of torasemide and furosemide on clinical and biochemical parameters of haemodynamic and neurohormonal compensation and myocardial remodelling. Secondary objectives include monitoring of: changes in signs and symptoms of heart failure, NYHA functional class, quality of life, dosage changes, rate of readmissions and mortality. DISCUSSION: Despite decades of the diuretic's history, knowledge about diuretic therapy is still unsatisfactory. The most widely used diuretic, furosemide, has a stormy pharmacokinetics and pharmacodynamics, and is associated with a high risk of mortality and hospitalization for worsening heart failure. Reports are very encouraging and suggest beneficial effects of torasemide. Hence, there is a need for further studies of the overall effect of torasemide, compared with furosemide. This can translate into improved quality of life and better prognosis of patients with heart failure. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01942109 . Registered on 24 August 2013.
引用
- Balsam P, Ozierański K, Tymińska A, et al. The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure - TORNADO: a study protocol for a randomized controlled trial. Trials. 2017. PMID: 28114980. doi:10.1186/s13063-016-1760-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。